Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K042324
    Manufacturer
    Date Cleared
    2004-10-07

    (41 days)

    Product Code
    Regulation Number
    862.1660
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Lyphochek Elevated Immunosuppressant Control is intended for use as a whole blood quality control to monitor the precision of laboratory procedures for cyclosporine testing.

    Device Description

    This product is prepared from human whole blood with added chemicals and preservatives. This product is provided in lyophilized form for added stability.

    AI/ML Overview

    This document describes the Lyphochek Elevated Immunosuppressant Control, a quality control material for cyclosporine testing.

    Here's an analysis of the acceptance criteria and the study that proves the device meets them:

    1. Table of Acceptance Criteria and Reported Device Performance

    The provided summary focuses on establishing substantial equivalence to a predicate device and stability claims. It does not present specific quantitative "acceptance criteria" in terms of performance metrics (like accuracy, precision, or bias) for cyclosporine testing itself, as it is a quality control material, not a diagnostic test. Instead, the "acceptance criteria" for this device relate to its stability and its comparison to a similar existing product.

    Acceptance Criteria CategorySpecific CriteriaReported Device Performance/Status
    Intended Use EquivalenceTo be used as a whole blood quality control to monitor the precision of laboratory procedures for cyclosporine testing. (Similar to predicate)Substantially Equivalent: Lyphochek Elevated Immunosuppressant Control is intended for the same purpose as the predicate device (Lyphochek Whole Blood Control), specifically tailored for cyclosporine.
    Form EquivalenceLyophilized (Similar to predicate)Substantially Equivalent: New device is lyophilized, matching the predicate.
    Matrix EquivalenceProcessed Human Whole Blood Lysate (Similar to predicate)Substantially Equivalent: New device uses processed human whole blood lysate, matching the predicate.
    Preservation EquivalenceContains preservatives (Similar to predicate)Substantially Equivalent: New device contains a broad-spectrum anti-microbial cocktail as a preservative, similar to the predicate. (Note: New device explicitly states it does not contain sodium azide, which is a specification rather than a direct criterion match, but it still has preservatives).
    Storage (Unopened)2°C to 8°C until expiration date (Similar to predicate)Reported Performance: Three years and three months when stored at 2 to 8 °C. Study: Real-time studies are ongoing to support this claim.
    Reconstituted Vial Claim14 days at 2°C to 8°C (Similar to predicate)Reported Performance: 14 days when stored tightly capped at 2 to 8°C (Open vial Stability). Study: Stability studies performed.
    Reconstituted and Freezing30 days when stored tightly capped at -10 to -20°C (Similar to predicate)Reported Performance: 30 days when stored tightly capped at -10 to -20°C (After reconstituting and freezing). Study: Stability studies performed.
    SafetyPreservative concentration not expected to cause a health hazard; does not contain sodium azide.Reported Performance: Broad-spectrum anti-microbial cocktail has individual ingredient concentrations less than 0.1%, not expected to cause a health hazard. Does not contain sodium azide. This meets regulatory expectations for safety regarding preservatives at these low concentrations.
    Substantial EquivalenceDemonstrates equivalence in terms of intended use, technological characteristics, and safety and effectiveness, despite minor differences (levels, specific analytes).FDA Determination: FDA has determined the device is substantially equivalent to legally marketed predicate devices, allowing it to proceed to market. This implies that the differences (bi-level vs. tri-level, specific analytes other than cyclosporine) were deemed not to raise new questions of safety or effectiveness.

    2. Sample Size Used for the Test Set and the Data Provenance

    The document does not explicitly state the "sample size used for the test set" in the context of typical algorithm validation (e.g., number of patient samples). The studies performed are stability studies and a comparison against a predicate device.

    • Stability Studies: The "sample size" for these would refer to the number of control vials tested at various time points and storage conditions. This information is not detailed in the summary.
    • Data Provenance: The studies were performed by the manufacturer, Bio-Rad Laboratories, and the data is internal to the company. The summary states "All supporting data is retained on file at Bio-Rad Laboratories." There is no mention of country of origin for the data or whether it was retrospective or prospective, other than the "real-time studies will be ongoing" for shelf life, indicating a prospective approach for that specific claim.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts

    This type of information is not applicable to this device. The Lyphochek Elevated Immunosuppressant Control is a quality control material, not a diagnostic device that requires expert interpretation of results or establishing a clinical ground truth. Its performance relates to its stability and its ability to consistently produce known (assigned) values for cyclosporine testing method monitoring. There are no "experts" establishing ground truth in the sense of clinical diagnosis.

    4. Adjudication Method for the Test Set

    This is not applicable to this device. Adjudication methods (like 2+1, 3+1) are used in clinical studies where multiple readers or experts provide interpretations that need to be resolved to form a definitive ground truth. As noted above, this device does not involve such human interpretation or ground truth establishment.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

    No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic imaging or similar devices where human readers interpret patient cases, and the AI's impact on their performance is being evaluated. The Lyphochek control is a material used to monitor an assay's precision, not a device that human readers interact with for interpretation.

    6. If a Standalone (i.e. algorithm only without human-in-the loop performance) was Done

    N/A. This device is a physical quality control material, not an algorithm. Therefore, "standalone algorithm performance" is not a relevant concept for it.

    7. The Type of Ground Truth Used

    For this device, the "ground truth" (or reference value) would be the assigned value of cyclosporine within the control material, established through a robust method (e.g., highly accurate reference method or a consensus of multiple clinical analyzers). The document does not explicitly detail how these assigned values are derived or what type of "ground truth" is used for the values themselves, but rather focuses on the stability of these values over time and storage conditions. The "ground truth" for the stability claims is the manufacturer's internal criteria for acceptable variation from specified values under different conditions.

    8. The Sample Size for the Training Set

    This is not applicable to this device. There is no "training set" as this is not an AI/ML algorithm or a device that learns from data.

    9. How the Ground Truth for the Training Set Was Established

    This is not applicable for the same reason as point 8.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1